BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Longeveron Begins Enrollment of Second Cohort of Phase 1 Alzheimer’s Disease Trial
Longeveron Enters Phase 1 Alzheimer's Trial

Longeveron Begins Enrollment of Second Cohort of Phase 1 Alzheimer’s Disease Trial

May 10, 2017 By Cade Hildreth (CEO) Leave a Comment

MIAMI, May 10, 2017 — Longeveron companyLongeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.

Discover class-defining bioproduction tools.

The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.

Barry Baumel, M.D. Principal Investigator and Director of the Memory Disorders Clinical Trials Group of the Department of Neurology at the University of Miami’s Miller School of Medicine stated, “The first five patients in our program have so far shown that the use of LMSCs in Alzheimer’s disease is safe.” Baumel continued, “We’re now going to continue to enroll and treat patients to see if stem cell treatment is effective in changing the typical worsening course of Alzheimer’s disease.”

Rooster DevServices

The DMC is an independent group of experts that regularly reviews data from ongoing clinical trials and reports their findings to the trial sponsor regarding continued safety of trial subjects and potential subjects as well as the validity and scientific merit of the trial.

Longeveron Begins Phase 1 Alzheimer's Trial

bitbio

Longeveron acknowledges the generous support of the Alzheimer’s Association through its Part of the Cloud Challenge on Neuroinflammation Grant.

To learn about participating in the clinical trial, visit: https://clinicaltrials.gov/ct2/show/NCT02600130

Pluristyx

About Longeveron

Longeveron is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas include Alzheimer’s disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility. www.longeveron.com

Rate this post

Filed Under: MSCs, Press Releases, Stem Cells Tagged With: allogeneic, Alzheimer's, LMSCs, Longeveron, mesenchymal stem cells

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.